ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 0.80 0.80 0.80 0.00 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.54 2.2M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 4.05p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.20 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.54.

Evgen Pharma Share Discussion Threads

Showing 9401 to 9418 of 13025 messages
Chat Pages: Latest  377  376  375  374  373  372  371  370  369  368  367  366  Older
DateSubjectAuthorDiscuss
16/7/2021
12:23
If not him then someone is happy to add in 100k and 250k chunks at full on Bid, +ve afternoon ahead. GLA
tburns
16/7/2021
12:06
Looks like John Kight is adding to his already large holding from recent trades
tburns
16/7/2021
10:53
That's a worry!!
peanut100
16/7/2021
10:45
FinnCap is the best small cap broker of 2021 peanut. See here:
on target
16/7/2021
10:26
It's time for a new broker - Numis or Liberum for me.
peanut100
15/7/2021
22:11
on target, considering the price movement over the last 12 months, not holding this stock for long seems a very sensible approach.
kingalf
15/7/2021
13:17
Short-term 'traders' i.e. those that can't hold onto a stock for more than a day or two would have bought yesterday or Friday and are now ditching it to chase another rainbow.
on target
15/7/2021
13:07
Buyers coming in now.

Yes there seems to be a lot of 'tree shaking' going on across the board.
Small PIs being worried-out to the advantage of the bigger boys.

on target
15/7/2021
12:14
I am puzzled with the price action here. I really thought we would at least leave 5p behind after those recent RNS's. Maybe the market wants to see if Huw et al are going to be buying, before committing funds/further funds themselves. I know I am now.
lovewinshatelosses
15/7/2021
10:56
Games continue ... I've emailed house broker... asked them, what's going on with SPand what are you earning your corn for !!
amaretto1
14/7/2021
14:09
I see that MonkeyMunch has gone over to UKOG bb (his previous ramping grounds) to do some ramping there, having failed over here? He was last ramping UKOG at 11.00p a share, and he has now started ramping UKOG at 0.17 a share! What an 1D10T !!! Now for his outburst!
🤣 🤣 🤣 !

jack4691
14/7/2021
10:27
James Robert Kight now up to 4% -
tomboyb
13/7/2021
21:54
Happy with the newsflow today and good to see a new large holder come on board. Hopefully sticky hands. Might buy more myself if we see decent inside buying shortly. Might anyway, to be honest! GLA.
lovewinshatelosses
13/7/2021
19:47
Maybe will buy tomorrow now AGM out the way
peanut100
13/7/2021
19:33
Director's buys, first thing tomorrow maybe
tburns
13/7/2021
18:56
Why not release this last bit of news first thing tomorrow....
peanut100
13/7/2021
18:04
"Extremely well funded" clocktower...Gl ;-)

9/7/21

"The Company mounted a rapid and important response to the current pandemic advised by colleagues in Dundee. From our point of view, the programme was always opportunistic and driven by urgent clinical need. The financial contribution from Evgen was not significant and we reiterate that our core programmes remain oncology focused. Complementing our positive phase 2 clinical data in metastatic breast cancer we have recently reported further positive data in cells derived from patients who had developed resistance to the widely used class of CDK4/6 inhibitors. We have also recently reported compelling data in pre-clinical models in glioblastoma from two academic centres. The Company is extremely well funded and we look forward to updating the market further as our oncology data sets strengthen and will continue to pursue attractive commercial opportunities for SFX-01."

moneymunch
Chat Pages: Latest  377  376  375  374  373  372  371  370  369  368  367  366  Older

Your Recent History

Delayed Upgrade Clock